ArticleFrontiers in neuroscience2019
Challenge and Prospect of Traditional Chinese Medicine in Depression Treatment.
Article in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Microbiota-Derived SCFAs Mediate the Synergistic Antidepressant Effects of Dajianzhong Decoction and Ketamine via FFAR2-NLRP3-IL-1β Signaling.Pharmaceuticals (Basel, Switzerland) · 2026Article
- LLMs and AI Life Models for Traditional Chinese Medicine-derived Geroprotector Formulation.Aging and disease · 2025Article
- (-)-Syringaresinol Exerts an Antidepressant-like Activity in Mice by Noncompetitive Inhibition of the Serotonin Transporter.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Analysis of medication rule of Traditional Chinese Medicine in treating depression based on data mining.Heliyon · 2024Article
- Exploring the transformative impact of traditional Chinese medicine on depression: Insights from animal models.World journal of psychiatry · 2024Review
- Constituents, pharmacological activities, pharmacokinetic studies, clinical applications, and safety profile on the classical prescription Kaixinsan.Frontiers in pharmacology · 2024Review
- Molecular basis and mechanism of action ofChinese herbal medicines · 2023Review
- Tao-Hong-Si-Wu decoction improves depressive symptoms in model rats via amelioration of BDNF-CREB-arginase I axis disorders.Pharmaceutical biology · 2022Article
- Antidepressant effects of total alkaloids ofPharmaceutical biology · 2022Article
- CPMCP: a database of Chinese patent medicine and compound prescription.Database : the journal of biological databases and curation · 2022Article
- Potential Anti-Depressive Effects and Mechanisms of Zhi-Zi Hou-Po Decoction Using Behavioral Despair Tests Combined WithFrontiers in pharmacology · 2022Article
- Integrated 16S rRNA sequencing and metabolomics analysis to investigate the antidepressant role of Yang-Xin-Jie-Yu decoction on microbe-gut-metabolite in chronic unpredictable mild stress-induced depression rat model.Frontiers in pharmacology · 2022Article
- Perspectives of herbs and their natural compounds, and herb formulas on treating diverse diseases through regulating complicated JAK/STAT signaling.Frontiers in pharmacology · 2022Review
- Potential therapeutic effect and methods of traditional Chinese medicine on COVID-19-induced depression: A review.Anatomical record (Hoboken, N.J. : 2007) · 2021Review
- Chinese Herbal Medicine for the Treatment of Depression: Effects on the Neuroendocrine-Immune Network.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A Traditional Chinese Medicine Plant Extract Prevents Alcohol-Induced Osteopenia.Frontiers in pharmacology · 2021Article
- Serum Metabolic Profiling Reveals the Antidepressive Effects of the Total Iridoids ofFrontiers in pharmacology · 2020Article
- Traditional Chinese Medicine in Depression Treatment: From Molecules to Systems.Frontiers in pharmacology · 2020Review
- Article
- Botanicals as modulators of depression and mechanisms involved.Chinese medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Current medication for depression is inadequate and far from ideal. Development of novel antidepressant drugs is a pressing task. The discovery of ketamine and related agents represents a new era in drug discovery for the rapid treatment of depression. Due to potential neurotoxicity, short-lasting efficacy, the limitation of a single target approach, and a limited role in depression prevention of these agents, additional approaches or drugs that exert synergy and compatibility, with the rapid-acting agents are required for better treatment of depression. Traditional Chinese Medicine (TCM) is a systems medicine and its clinical experience and integrated theory for diagnosis and treatment provides an alternative method of novel drug discovery in depression treatment. In TCM, there are numerous claimed effective antidepressant formulas, but comprehensive research and evidence-based clinical studies are required for their acceptance as a treatment. In this essay, we review current attempts in the discovery of new agents, TCM drug formulation, and TCM treatment of depression, and discuss the challenges and opportunities of TCM in the new era of antidepressant discovery. TCM could provide an important resource in the discovery of novel agents, assistance of the rapid-acting antidepressants, development of new agents for female patients, and the prevention of depression at its early stages. The study of depression in conjunction with TCM therefore not only provides an opportunity to scientifically evaluate the benefits and risks of TCM, but also accelerates the development of novel antidepressant agents by combining the principle of modern molecular medicine with the ideas of empirical systems medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.